Tumor necrosis factor-α (TNFα) was cloned over 2 decades ago and its identification in part
led to the discovery of a super family of tumor necrosis factors (TNFs) and their receptors …

Objectives To compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab
(INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS) …

Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

Objectives To assess the efficacy and safety of switching from the infliximab reference
product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 …

Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth …

Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty …

Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …

Importance The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled,
moderate to severe atopic dermatitis (AD). Objective To assess the efficacy and safety of …

Background We did a randomised controlled trial to assess the benefit of maintenance
infliximab therapy in patients with active Crohn's disease who respond to a single infusion of …

TNF was originally described as a circulating factor that can cause necrosis of tumours, but
has since been identified as a key regulator of the inflammatory response. This review …